High-dose ergocalciferol in patients on hemodialysis: A pilot trial

Elisa Elena del Valle(Universidad del Salvador), José Zanchetta(Universidad del Salvador), Erich Fradinger(Universidad del Salvador), Aikaterini Marini(Instituto de Diagnóstico e Investigaciones Metabólicas), Soledad Crucelegui(Instituto de Diagnóstico e Investigaciones Metabólicas), Luis Sintado(Instituto de Diagnóstico e Investigaciones Metabólicas), J Ryba(Instituto de Diagnóstico e Investigaciones Metabólicas), Pablo Bevione(Instituto de Diagnóstico e Investigaciones Metabólicas), Armando Negri(Universidad del Salvador), G. Rosa Diez(Instituto de Diagnóstico e Investigaciones Metabólicas), Marcelo Puddú(Instituto de Diagnóstico e Investigaciones Metabólicas), Manuel Canalis(Instituto de Diagnóstico e Investigaciones Metabólicas)
Bone
January 11, 2016
10.1016/j.bone.2014.12.050
Cited by 0

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497